Biostar Pharmaceuticals, Inc. Announces 2011 Fourth Quarter And Year-end Financial Results

XIANYANG, China, March 27, 2012 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the fourth quarter and year ended December 31, 2011.

Fourth Quarter 2011 vs. 2010

  • Net sales decreased 8.1% to $25,985,024 from $28,277,390;
  • Gross margin was 68.3% as compared to 76.1%;
  • Income from operations decreased to $2,542,230, compared to $8,122,473; and,
  • Net income decreased to $833,630, or $0.03 per diluted share, compared to $6,105,736, or $0.22 per diluted share.

Full Year 2011 vs. 2010

  • Net sales increased 14.6% to $91,965,505 from $80,214,873
  • Gross margin was 70.0% as compared to 75.0%;
  • Income from operations decreased to $18,159,054, compared to $23,610,274; and,
  • Net income decreased to $12,173,513, or $0.44 per diluted share, compared to $17,381,560 or $0.63 per diluted share.

Ronghua Wang, Biostar's Chief Executive Officer and Chairman commented, "Net sales for the 2011 fourth quarter declined by approximately $2.3 million from the same period of 2010, mainly due to lower net sales of our flagship product, Xin Aoxing Capsule. To combat increased competition facing our Xin Aoxing Capsule, in mid-2011 we started a 'Buy 3 Get 1 Free' promotion, and as a result, sales volume increased, but net sales decreased by approximately $2.7 million from the 2010 fourth quarter. Since the start of this promotion, gross margin for Xin Aoxing Capsule has declined, but continues to remain above 80%."

Mr. Wang continued, "For all the other products, although sales volume increased, selling prices were depressed due to the Chinese government's price control policy through its drug-tendering model called 'lowest-price-win' Anhui EDL (essential drug list). This accounted for much of the decline in gross margin. Notwithstanding the lower selling prices, however, for 2011 as a whole, net sales increased by approximately $11.8 million or 14.6%. This was a direct result of our ongoing efforts to gain market share in our current locations, as well as, to expand our operations into new provinces.

"Of note, Xin Aoxing Capsule continues to be our main growth catalyst, as net sales for 2011 increased by 13.2% to $60.5 million and represented 65.8% of net sales compared to $53.4 million or 66.6% of 2010 net sales. Additionally, product sales from the newly acquired Shaanxi Weinan which we acquired in October 2011, contributed approximately $836,000 in total net sales for the 2011 fourth quarter and the year. Net sales from rural markets were approximately $4.8 million and $16.3 million for the 2011 fourth quarter and year, respectively. We continue to focus much of our marketing efforts in rural areas where there is less competition and more patients in need of our pharmaceutical and health products."

Mr. Wang noted, "Another persistent reason for the decline in gross margin for the 2011 fourth quarter and the year has been the significant increase of raw materials costs, especially those used in Taohuasan Pediatrics Medicine and Tianqi Dysmenorrhea Capsule.  To control costs and enhance quality of our raw materials, we have planted 13 herbs at our 82 acre plantation in Qinling Mountains, two of which, salvia miltiorrhiza and honeysuckle, have been harvested and are being used to produce Danshen Granule and a health product. Other herbs should be ready for harvest in 2012. We plan to either trade these herbs for other raw materials or sell them."

Mr. Wang added, "2011 operating expenses as a percentage on net sales increased to 50.3% as compared to 45.5% in 2010, due to (i) higher advertising expenditures, (ii) $1.5 million higher general and administrative expenses mainly related to stock-based compensation and the acquisition of Shaanxi Weinan in late 2011, and (iii) a $2.3 million increase in research and development expenses for acquiring a proprietary technology used to manufacture a medicine to fight a cardiovascular and cerebrovascular disease, recorded in the fourth quarter of 2011. Additionally, in the fourth quarter, we recorded a non-cash $1.8 million impairment loss on land use rights for the construction of a raw materials processing plant in Zouan Town and another piece of land adjacent to our headquarters in Xianyang which was reclaimed by the local government. As a result, net income for 2011 fourth quarter and the year declined to approximately $0.8 million ($0.03 per diluted share) and approximately $12.2 million ($0.44 per diluted share), respectively, compared to approximately $6.1 million and approximately $17.4 million in the corresponding periods of 2010."

Biostar's CFO, Zack Pan noted, "Our balance sheet remains strong. Total current assets at December 31, 2011 were $60.5 million vs. total current liabilities of $6.7 million for a 9.1:1 current ratio. We continue to fund our business from our free cash flow. As of December 31, 2011, we had cash and cash equivalents of approximately $17 million compared to approximately $13.2 million one year earlier. Net cash provided by operating activities through December 31, 2011 was approximately $8.8 million; net cash used in investing activities in 2011 was approximately $6.3 million. We believe our existing cash and cash equivalents are sufficient to fund our current operations."

Mr. Wang added, "We continue to execute our strategy to grow our Company organically and through acquisitions. In 2011, we expanded our geographic coverage by adding three new provinces into our network, for a total of 25 provinces, and have increased our rural presence in the province of Shaanxi to approximately 13,000 sales outlets. To further increase our market share, we have expanded our sales force to over 400 people and increased our advertising spending. Additionally, we continue to invest in the development of several innovative products. Our team of 30 scientists and researchers continues to develop new products and we currently have eight OTC products and prescription drugs in our pipeline. "

Mr. Wang noted, "With the 2011 acquisition of Shaanxi Weinan, we increased our portfolio of drug approvals and permits by an additional 86 drugs and one health product. Currently, we are manufacturing eleven products at Shaanxi Weinan's facilities, and we expect to generate over $5 million in net sales in 2012 from the sale of these products."

Mr. Wang concluded, "We believe that Biostar is well positioned to take advantage of opportunities in China's pharmaceutical market, ranked the third largest in the world in 2011, over $50 billion in size and with growth projected at more than 20% in the next five years.  Our large portfolio of drug approvals and permits, state-of-the-art research laboratories, high-tech production facilities, large distribution network and geographic coverage, are the foundations for our continued growth. To address the significant unmet needs of its population, China's $124 billion healthcare reform plan, launched in 2009, has made accessibility and affordability two major government guidelines.  Our business plan works well with those goals. Additionally, we participate in the New Rural Medical Care Cooperative Program launched by the Chinese government in 2008, and benefit from greater numbers of people seeking  medicines offered in hospitals and healthcare centers. We expect to announce 2012 revenue guidance when we issue our results for the first quarter of 2012."

Conference Call

Biostar's Chairman and CEO, Ronghua Wang and CFO, Zack Pan will host a conference call today, Tuesday, March 27th at 10:00 am E.T. to discuss these results as well as recent corporate developments.

Live conference call details

Interested parties may participate in the call by dialing (480) 629-9808. Please call in 10 minutes before the conference is scheduled to begin and ask for the Biostar call or use pass code 4527039. After opening remarks, there will be a question and answer period.  Questions may be asked during the live call, or alternatively, you may e-mail questions in advance to lcati@equityny.com.

Webcast

The conference call will also be broadcast live over the Internet. To listen to the webcast, please go to http://viavid.net/dce.aspx?sid=0000954F or visit Biostar's website http://www.biostarpharmaceuticals.com and then to the Event Calendar page where the conference call is posted.  Please go to the website at least 15 minutes early to register, and download and install any necessary audio software.  If you are unable to listen live, the conference call will be archived and can be accessed for approximately 90 days. We suggest listeners use Microsoft Internet Explorer as their web browser.

Replay

A reply will be available until 11:59 pm E.T. April 3, 2012. To listen, please call (858) 384-5517 and use pass code 4527039.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to complete this acquisition, its ability to capitalize on the market opportunities presented by such acquisition, regulatory and other related approvals relating to the proposed acquisition, the Company's ability to integrate the recently acquired Shaanxi Weinan product lines into the Company's current product line and current operations, its ability to complete the audit and other closing conditions relating to the proposed acquisition,  success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:  

BioStar Pharmaceuticals, Inc.

The Equity Group, Inc.

Zack Pan, CFO

Lena Cati

Tel: 405-996-8829

Tel: 212 836-9611

Email: zpan@aoxing-group.com 

Email: lcati@equityny.com

~FINANCIAL TABLES FOLLOW~


BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 Year Ended 

 

 

 December 31,

 

 

2011

 

2010

 

 

 

 

 

Sales, net

 

$      91,965,505

 

$    80,214,873

Cost of sales

 

27,578,441

 

20,079,377

Gross profit

 

64,387,064

 

60,135,496

Operating expenses:

 

 

 

 

Selling expenses

 

38,227,362

 

32,313,284

General and administrative expenses

 

5,676,652

 

4,175,828

Research and development expenses

 

2,323,996

 

36,110

Total operating expenses

 

46,228,010

 

36,525,222

Income from operations

 

18,159,054

 

23,610,274

Other income (expense)

 

 

 

 

Interest income

 

430,021

 

34,020

Interest expense

 

(41,942)

 

-

Other income (expense)

 

713

 

(192,751)

Gain from bargain purchase

 

1,299,063

 

-

Impairment loss on land use rights

 

(1,784,072)

 

-

Foreign exchange gain

 

3,313

 

3,154

Total other income (expense)

 

(92,904)

 

(155,577)

Income before income taxes

 

18,066,150

 

23,454,697

Provision for income taxes

 

5,892,637

 

6,073,137

Net income

 

$      12,173,513

 

$      17,381,560

Earnings per share

 

 

 

 

      Basic

 

$                 0.44

 

$                 0.66

      Diluted

 

$                 0.44

 

$                 0.63

Weighted average number of common stock outstanding

 

 

 

 

      Basic

 

27,894,222

 

26,357,954

     Diluted

 

27,894,222

 

27,468,724


BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

December 31,

 

December 31,

 

2011

 

2010

 

 

 

 

ASSETS

 

 

 

Current Assets

 

 

 

Cash and cash equivalents

$       16,971,789

 

$      13,211,443

Accounts receivable

35,033,650

 

28,535,712

Inventories

1,373,459

 

351,682

Prepaid expenses and other receivables

7,129,911

 

1,251,397

Total Current Assets

60,508,809

 

43,350,234

 

 

 

 

Deposits

3,148,466

 

7,713,482

Deferred tax assets

1,617,688

 

-

Property and equipment, net

7,379,982

 

5,958,636

Intangible assets, net

10,406,931

 

11,064,591

Total Assets

$       83,061,876

 

$      68,086,943

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

Current Liabilities

 

 

 

Accounts and other payables

$         3,334,418

 

$        3,991,071

Short-term bank loans

787,116

 

-

Value-added tax  payable

895,487

 

1,509,173

Income tax payable

1,643,155

 

2,086,702

Total Current Liabilities

6,660,176

 

7,586,946

 

 

 

 

Commitment and contingencies

 

 

 

Stockholders' Equity

 

 

 

Common stock, $.0001 par value, 100,000,000 shares authorized, 28,196,627 and 27,387,436 shares issued and outstanding as of December 31, 2011 and  2010

28,196

 

27,387

Additional paid-in capital

22,426,864

 

20,706,667

Statutory reserve

6,490,600

 

4,666,381

Retained earnings

43,473,834

 

33,124,540

Accumulated other comprehensive income

3,982,206

 

1,975,022

Total Stockholders' Equity

76,401,700

 

60,499,997

Total Liabilities and Stockholders' Equity

$       83,061,876

 

$      68,086,943

 

BIOSTAR PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 Year ended  December 31,

 

2011

 

2010

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

Net income

$           12,173,513

 

$          17,381,560

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Deferred tax assets

(299,960)

 

-

Depreciation and amortization

885,118

 

620,024

Research and development expenses

2,332,681

 

-

Impairment loss on land use rights

1,784,072

 

-

Stock-based compensation and other non-cash expenses

1,721,006

 

681,716

Make good shares expense

-

 

187,000

Gain from bargain purchase

(1,299,063)

 

-

Changes in operating assets and liabilities:

 

 

 

      Accounts receivable

(5,332,216)

 

(8,057,168)

      Inventories

(609,967)

 

(11)

      Prepaid expenses and other receivables

(10,000)

 

314,794

      Accounts payable and accrued expenses

(1,638,295)

 

310,452

      Value-added tax payable

(675,338)

 

423,325

      Income tax payable

(528,792)

 

554,939

     Exchange difference

270,488

 

424,801

Net cash provided by operating activities

8,773,247

 

12,841,432

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

Purchase of property and equipment

(110,585)

 

(1,466,486)

Acquisition of business

(4,037,700)

 

-

Acquisition of proprietary technologies

-

 

(265,150)

Deposit paid for acquisition of proprietary technologies

(3,119,798)

 

(2,268,671)

Refund of deposit paid for acquisition of business

928,361

 

-

Deposit paid for acquisition of business

-

 

(4,537,342)

Net cash used in investing activities

(6,339,722)

 

(8,537,649)

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

Advance from a shareholder

334,957

 

-

Repayment to a shareholder

(334,957)

 

-

Proceeds from short-term bank loans

787,116

 

-

Proceeds from issuance of common stock

-

 

37,537

Net cash provided by financing activities

787,116

 

37,537

Effect of exchange rate changes on cash and cash equivalents

539,705

 

292,419

Net increase in cash and cash equivalents

3,760,346

 

4,633,739

Cash and cash equivalents, beginning balance

13,211,443

 

8,577,704

Cash and cash equivalents, ending balance

$            16,971,789

 

$          13,211,443

SUPPLEMENTAL DISCLOSURES:

 

 

 

Interest received

$                 430,021

 

$                 34,020

Interest payments

$                 (41,942)

 

$                          -

Income tax payments

$            (6,699,145)

 

$          (5,531,902)

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

Conversion of preferred stock to common stock

$                             -

 

$                  3,160

Cashless exercise of warrants

$                             -

 

$                     815

Prior year deposit paid for acquisition of property and equipment

$                             -

 

$              439,016

Prior year deposit paid for acquisition of business

$              4,722,699

 

$                          -

Payable for acquisition of business

$                 818,601

 

$                          -

Reclassification of land use rights  to other receivables

$            (5,821,168)

 

$                          -

SOURCE Biostar Pharmaceuticals, Inc.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here